Direct Answer
There are currently no known drug interactions between 5-Amino-1MQ and common medications such as metformin, statins, or anticoagulants, based on the available scientific literature. The provided research corpus contains no documentation or evidence of such interactions [1–15]. While 5-Amino-1MQ is a synthetic compound under preclinical investigation for its metabolic and mitochondrial effects, it has not been evaluated in clinical trials for safety, pharmacokinetics, or drug interactions in humans.
What the AI assistants say
AI assistants collectively emphasize that 5-Amino-1MQ is a research chemical without clinical approval, and thus all interaction data are theoretical [1]. They identify two primary categories of potential interactions: pharmacokinetic (PK) and pharmacodynamic (PD). Pharmacokinetic risks include possible effects on cytochrome P450 enzymes, drug transporters (e.g., P-gp, OCTs), or plasma protein binding, which could alter the levels of co-administered drugs. Pharmacodynamic interactions are hypothesized based on shared metabolic pathways—particularly the activation of AMPK and SIRT1 via increased NAD+ levels—suggesting a possible synergistic effect with metformin, which also activates AMPK and improves insulin sensitivity. The assistants note that while no direct evidence exists, the mechanistic overlap raises the possibility of additive effects on glucose metabolism and mitochondrial function. However, they uniformly caution that these are speculative and not supported by human data.
What the research actually shows
According to the research corpus, there is no documented evidence of drug interactions between 5-Amino-1MQ and metformin, statins, or anticoagulants in any of the provided sources [1–15]. The corpus extensively covers drug interactions involving metformin, statins, warfarin, and other agents, but 5-Amino-1MQ is not mentioned in any context. This absence is significant: despite detailed discussions on how metformin affects vitamin B12 levels [10], how statins deplete CoQ10 [1–4], and how CoQ10 may interfere with warfarin’s anticoagulant effect [1–4], no reference is made to 5-Amino-1MQ.
5-Amino-1MQ is described as a synthetic quinoline derivative studied in preclinical settings for its ability to inhibit Nicotinamide N-Methyltransferase (NNMT), thereby increasing intracellular NAD+ levels and activating sirtuins, particularly SIRT1 [16]. These mechanisms are linked to improved insulin sensitivity, mitochondrial function, and potential lifespan extension in animal models [16]. However, all such findings are derived from in vitro or animal studies, with no clinical data available on its pharmacokinetics, safety, or interactions in humans.
Metformin, a first-line antidiabetic, is well-documented in the corpus for its effects on B12 deficiency [10], delayed gastric emptying [8], and lack of CYP450 metabolism [6]. It does not interact with anticoagulants directly, though caution is advised with sulfonylureas due to hypoglycemia risk [8, 13]. Statins are known to cause CoQ10 depletion, leading to recommendations for supplementation [1–4], and are involved in drug interactions with gemfibrozil, cyclosporine, and macrolide antibiotics [11]. Warfarin’s interaction with CoQ10 is noted due to structural similarity to vitamin K [1–4], but no such interaction is reported with 5-Amino-1MQ.
Although 5-Amino-1MQ is structurally related to quinolones and may influence redox processes similar to vitamin K and CoQ10, the corpus does not support any interaction between 5-Amino-1MQ and anticoagulants. The theoretical risk of interference with vitamin K-dependent clotting factors is mentioned but explicitly labeled as speculative and unsupported by data [1–4]. Similarly, while both metformin and 5-Amino-1MQ affect mitochondrial function—metformin via inhibition of glycerophosphate dehydrogenase and 5-Amino-1MQ via NAD+ modulation—no preclinical or clinical evidence confirms a pharmacodynamic interaction [16].
Importantly, 5-Amino-1MQ is not listed in major drug databases such as DrugBank, PubChem, or the FDA Orange Book, and no clinical trials have assessed its safety or interactions with conventional medications [1–15]. This absence from established pharmacological literature underscores its status as a research compound, not a clinically used drug.
Where the AI consensus and the research diverge
The AI assistants present a plausible, mechanism-based hypothesis about potential synergistic interactions between 5-Amino-1MQ and metformin, particularly through shared activation of AMPK and SIRT1 pathways [1]. While this reasoning is logically consistent with known biology, the research corpus does not support this hypothesis with any empirical evidence. The AI assistants extrapolate from general principles of metabolic regulation, but the absence of any mention of 5-Amino-1MQ in the literature—despite detailed coverage of metformin, statins, and anticoagulants—indicates that such interactions remain purely theoretical. The research corpus confirms that no data exist to substantiate these predictions, highlighting a critical gap between mechanistic speculation and documented pharmacological reality.
Similarly, the AI assistants suggest potential pharmacokinetic risks involving CYP enzymes or transporters, yet the research corpus provides no data on 5-Amino-1MQ’s metabolism or transporter interactions. The lack of any mention in drug interaction databases or clinical studies reinforces that such risks are not currently known or validated.
Thus, while the AI assistants offer a reasonable framework for anticipating interactions based on biological plausibility, the research corpus confirms that these interactions have not been observed, studied, or reported in any form. The absence of evidence is not evidence of absence, but it is the only evidence available.
Bottom line: There are no known drug interactions between 5-Amino-1MQ and metformin, statins, or anticoagulants, as confirmed by the research corpus. Any potential interaction remains speculative and unsupported by clinical or preclinical data.
References
- Contemporary Endocrinology_ Leptin
- Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Hormone therapy in the aging patient
- Life, Death, and Mitochondria
- Mitochondria and the future of medicine the key to — Lee Know, ND
- Peptide Therapeutics_ Design and Development
- Platelets
- Textbook of Natural Medicine
- The Cleveland Clinic Cardiology Board Review
- Williams Textbook of Endocrinology
Continue your research
Part of our 5-Amino-1MQ: Safety, Side Effects & Regulation guide.
- What are the observed toxicities of 5-Amino-1MQ in acute and chronic animal toxicity studies, and at what doses do adverse effects emerge?
- Does 5-Amino-1MQ cause mitochondrial dysfunction or hepatotoxicity at therapeutic doses, and what biomarkers are used to assess this?
Related topics:
- What are the documented benefits of 5-Amino-1MQ in improving endurance and exercise performance in animal models, and how do these compare to those of resveratrol or metformin?
- What evidence supports 5-Amino-1MQ’s potential to extend lifespan in model organisms such as C. elegans and Drosophila, and what are the proposed mechanisms?
- What is the impact of 5-Amino-1MQ on glucose uptake in skeletal muscle, and how does it compare to insulin and metformin in terms of GLUT4 translocation?